Posted by admin | Posted in Herbal Remedies | Posted on 13-05-2011
Tags: bone, health, osteoporosis, osteoporosis postmenopausal, osteoporosis postmenopausal physiopathology, osteoporosis postmenopausal treatment, osteoporosis postmenopausal women, osteoporosis postmenopausal women diagnosis monitoring, pharmaceutical, postmenopausal
39% of postmenopausal women with low bone density (osteopenia), placing them at risk for osteoporosis with ENS?
39% of postmenopausal women with low bone density (osteopenia), placing them at risk for osteoporosis with spontaneous fractures that result. Osteoporosis is estimated at 14 billion dollars annually in medical costs alone, and yet it can be prevented if treated soon enough. A group of doctors to 249 postmenopausal women with a primary diagnosis and 81 with low bone density. (A) What is the probability only 81 or less than 249 patients have low bone density? Find the probability using the binomial probability model (b) Find the probability of (a) using the normal approximation to the binomial distribution.
qa binomial probability model n = 249, p = 0.39, P = 0.61 q [k] NCK * = p ^ k * q ^ (nk) P [<= 81] = P [0] + P [1] + ... + P [81] using a calculator binomial, P [<= 81] = 0.0204 qb or 2.04% for the normal approximation to the binomial distribution, mean = np = 97.11, SD = sqrt (npq) = 7.697 under the continuity correction for using a continuous distribution for a discrete distribution, <= 81 is <= 81.5 z = value of [81.5 to 97.11] / 7.697 = - 2.03 reqd. Probability = 0.0212, or 2.12%
US $24.00
 |
Denosumab for the Management of Postmenopausal Osteoporosis (Postgraduate Medicine) List Price: $9.99  |
|
Postmenopausal osteoporosis is a major concern to public health. Fractures are the major clinical consequence of osteoporosis and are associated with substantial morbidity, mortality, and health care costs... |
 |
Postmenopausal Osteoporosis: Hormones and Other Therapies (Controversial Issues in Climacteric Medicine) List Price: $149.95 Sale Price: $37.38 Used From: $24.26 |
|
The book is the first major review of menopause-associated osteoporosis, post WHI. The book has in-depth sections on the pathogenesis, epidemiology, and diagnosis of osteoporosis. The chief focus is on medical prevention and treatment, and includes chapters on hormone replacement therapy, bisphosphonates, selective estrogen receptor modulators (SERMs), vitamin D derivatives, calcium supplements, androgens, and tibolone. |
 |
Once-a-Month Risedronate in Postmenopausal Osteoporosis (Postgradaute Medicine) List Price: $2.99 |
|
Abstract: Original Article Delmas PD, McClung MR, Zanchetta JR, et al. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone. 2008;42(1):36–42PRACTICE PEARL This study demonstrates the efficacy, safety, and convenience of once-a-month risedronate versus a once-daily dose... |
 |
POSTMENOPAUSAL OSTEOPOROSIS: Strategies for preventing bone loss, avoiding fracture (Postgraduate Medicine) List Price: $9.99 |
|
Osteoporosis causes fractures in more than a million and a half Americans each year. About 80% of these fractures occur in women, often at or shortly after menopause. Can the factors responsible for bone loss at menopause be modified to reduce risks? In this article, Drs McGarry and Kiel explain who should undergo bone density testing, which tests are most helpful, and who should be offered preventive therapy... |